Video
- Author:
- Mary Ellen Schneider
Publish date: January 25, 2018
ATLANTA – Dr. Robert Brodsky shares his takeaways on the key practice changing data presented in the ASH 2017 late breakers.
News
- Author:
- Mary Ellen Schneider
Publish date: January 25, 2018
Patients outside the United States will be able to access the drug only through compassionate use programs.
Audio
- Author:
- Mary Ellen Schneider
Publish date: January 11, 2018
Dr. Stephen Ansell outlines the challenges in using immunotherapy effectively in non-Hodgkin lymphoma and future directions.
News
- Author:
- Mary Ellen Schneider
Publish date: January 2, 2018
The new indication includes treatment of adult patients with newly diagnosed chronic phase Philadelphia chromosome–positive CML.
News
- Author:
- Mary Ellen Schneider
Publish date: December 9, 2017
ATLANTA – The regimen combines a modified lentiviral vector with reduced exposure busulfan conditioning.
News
- Author:
- Mary Ellen Schneider
Publish date: December 6, 2017
The CAR T-cell therapy bb2121 was granted breakthrough therapy designation by the Food and Drug Administration, speeding its review process.
News
- Author:
- Mary Ellen Schneider
Publish date: November 28, 2017
Study pinpoints a new mechanism of gene regulation in acute myeloid leukemia.
News
- Author:
- Mary Ellen Schneider
Publish date: November 27, 2017
Several studies will focus on combination treatment approaches in MZL.
News
- Author:
- Mary Ellen Schneider
Publish date: November 21, 2017
The guidelines are based on studies and expert consensus.
News
- Author:
- Mary Ellen Schneider
Publish date: November 10, 2017
The generic is approved for pediatric patients up to 21 years old with relapsed or refractory ALL after two prior regimens.
News
- Author:
- Mary Ellen Schneider
Publish date: November 10, 2017
The study looks at response to standard-of-care regimens in younger patients.
News
- Author:
- Mary Ellen Schneider
Publish date: November 10, 2017
The observational study highlights the potential of the drug in a population of hard-to-treat patients.
News
- Author:
- Mary Ellen Schneider
Publish date: November 9, 2017
Phase 1 trials of UCART123 were halted in September but the FDA has given clearance for research to continue, with conditions.
News
- Author:
- Mary Ellen Schneider
Publish date: November 7, 2017
Dr. Charles E. Miller offers his top picks for research presentations at the 2017 AAGL Global Congress.
News
- Author:
- Mary Ellen Schneider
Publish date: November 6, 2017
Vemurafenib is now approved to treat ECD patients with the BRAF V600 mutation.
